From the Division of Vascular Neurology and Neurocritical Care, Department of Neurology, Baylor College of Medicine, Houston, TX (R.H.D., S.A.).
University of Texas Health Science Center at Houston School of Public Health (P.A.).
Stroke. 2018 Aug;49(8):2008-2010. doi: 10.1161/STROKEAHA.118.021109.
Background and Purpose- The aims of this study were to investigate the effect of an intervention to unblind data on r-tPA (recombinant tissue-type plasminogen activator) administration and sharing data with chief executive officers of participating hospitals, on r-tPA administration rates postintervention and on potential healthcare cost savings implemented at 26 Southeast Texas Regional Advisory Council hospitals. Methods- Retrospective analysis of prospective data on thrombolytic therapy from 26 Southeast Texas Regional Advisory Council hospitals, collected between April 2014 and June 2016. The control (blinded) period (Q2-2014 to Q2-2015) was followed by unblinding (Q3-2015). Results- Intervention was associated with 21.1% increase in r-tPA administration rates, with 38.5% increase in r-tPA administration with door-to-needle time ≤60 minutes. An absolute increase in r-tPA administration of 2.1% was seen with an average lifetime cost savings of $3.6 million. Conclusions- Transparent regional data sharing was associated with improved r-tPA administration and healthcare cost savings.
背景与目的-本研究旨在探讨对数据去盲的干预措施以及与参与医院的首席执行官分享数据对接受重组组织型纤溶酶原激活剂(r-tPA)治疗的影响,以评估其对德克萨斯州东南部 26 家区域咨询委员会医院干预后 r-tPA 使用率的影响,以及对潜在的医疗成本节约的影响。方法-对 26 家德克萨斯州东南部区域咨询委员会医院于 2014 年 4 月至 2016 年 6 月间收集的溶栓治疗前瞻性数据进行回顾性分析。以数据去盲(Q3-2015)前的盲态(Q2-2014 至 Q2-2015)为对照期。结果-干预措施与 r-tPA 使用率增加 21.1%相关,其中门到针时间≤60 分钟的 r-tPA 使用率增加 38.5%。r-tPA 使用率平均增加 2.1%,并产生了 360 万美元的平均终身成本节约。结论-透明的区域数据共享与提高 r-tPA 的使用率和降低医疗成本有关。